Instituto Português de Oncologia de Lisboa

Instituto Português de Oncologia de Lisboa Francisco Gentil (IPO Lisboa) is a premier public oncology center in Portugal, specializing in cancer treatment, research, and training. Established in 1923, it operates as a state-owned enterprise providing comprehensive multidisciplinary care, including advanced surgery, radiotherapy, and systemic therapies. The institute is a major hub for clinical research in Europe, hosting numerous Phase 1-3 clinical trials across various solid and hematological malignancies. It is particularly noted for its expertise in nuclear medicine, genetics, and the development of personalized medicine strategies. As a member of the Organisation of European Cancer Institutes (OECI), it maintains high standards of quality in patient care and scientific innovation.